<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Diabetes Investig</journal-id><journal-id journal-id-type="iso-abbrev">J Diabetes Investig</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)2040-1124</journal-id><journal-id journal-id-type="publisher-id">JDI</journal-id><journal-title-group><journal-title>Journal of Diabetes Investigation</journal-title></journal-title-group><issn pub-type="ppub">2040-1116</issn><issn pub-type="epub">2040-1124</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27762088</article-id><article-id pub-id-type="pmc">5415488</article-id><article-id pub-id-type="doi">10.1111/jdi.12588</article-id><article-id pub-id-type="publisher-id">JDI12588</article-id><article-categories><subj-group subj-group-type="overline"><subject>Short Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Articles</subject><subj-group subj-group-type="heading"><subject>Clinical Science and Care</subject></subj-group></subj-group></article-categories><title-group><article-title>Preventive effect of ipragliflozin on nocturnal hypoglycemia in patients with type 2 diabetes treated with basal&#x02010;bolus insulin therapy: An open&#x02010;label, single&#x02010;center, parallel, randomized control study</article-title><alt-title alt-title-type="left-running-head">Okajima <italic>et al</italic>.</alt-title></title-group><contrib-group><contrib id="jdi12588-cr-0001" contrib-type="author" corresp="yes"><name><surname>Okajima</surname><given-names>Fumitaka</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7588-6761</contrib-id><address><email>okaji@nms.ac.jp</email></address><xref ref-type="aff" rid="jdi12588-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jdi12588-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jdi12588-cr-0002" contrib-type="author"><name><surname>Nagamine</surname><given-names>Tomoko</given-names></name><xref ref-type="aff" rid="jdi12588-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jdi12588-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jdi12588-cr-0003" contrib-type="author"><name><surname>Nakamura</surname><given-names>Yuko</given-names></name><xref ref-type="aff" rid="jdi12588-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jdi12588-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jdi12588-cr-0004" contrib-type="author"><name><surname>Hattori</surname><given-names>Naomi</given-names></name><xref ref-type="aff" rid="jdi12588-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jdi12588-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jdi12588-cr-0005" contrib-type="author"><name><surname>Sugihara</surname><given-names>Hitoshi</given-names></name><xref ref-type="aff" rid="jdi12588-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jdi12588-cr-0006" contrib-type="author"><name><surname>Emoto</surname><given-names>Naoya</given-names></name><xref ref-type="aff" rid="jdi12588-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jdi12588-aff-0002">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="jdi12588-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Division of Endocrinology</named-content><named-content content-type="organisation-division">Department of Medicine</named-content><named-content content-type="organisation-division">Chiba&#x02010;Hokusoh Hospital</named-content><institution>Nippon Medical School</institution><named-content content-type="city">Chiba</named-content><country country="JP">Japan</country></aff><aff id="jdi12588-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Department of Endocrinology</named-content><named-content content-type="organisation-division">Diabetes and Metabolism</named-content><named-content content-type="organisation-division">Graduate School of Medicine</named-content><institution>Nippon Medical School</institution><named-content content-type="city">Tokyo</named-content><country country="JP">Japan</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Fumitaka Okajima<break/>
Tel.: +81&#x02010;476&#x02010;99&#x02010;1111<break/>
Fax: +81&#x02010;476&#x02010;99&#x02010;1908<break/>
E&#x02010;mail address: <email>okaji@nms.ac.jp</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>11</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2017</year></pub-date><volume>8</volume><issue>3</issue><issue-id pub-id-type="doi">10.1111/jdi.2017.8.issue-3</issue-id><fpage>341</fpage><lpage>345</lpage><history><date date-type="received"><day>25</day><month>8</month><year>2016</year></date><date date-type="rev-recd"><day>04</day><month>10</month><year>2016</year></date><date date-type="accepted"><day>16</day><month>10</month><year>2016</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2017 Asian Association for the Study of Diabetes and John Wiley & Sons Australia, Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2016 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley &#x00026; Sons Australia, Ltd</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JDI-8-341.pdf"/><abstract id="jdi12588-abs-0001"><title>Abstract</title><p>The efficacy of the administration of sodium&#x02010;glucose co&#x02010;transporter 2 inhibitor or the co&#x02010;administration of sodium&#x02010;glucose co&#x02010;transporter 2 inhibitor and dipeptidyl peptidase&#x02010;4 inhibitor to insulin therapy is not well known. A total of 58 patients with type 2 diabetes, admitted for glycemic control, were randomized to basal&#x02013;bolus insulin therapy (<styled-content style="fixed-case">BBT</styled-content>) alone or <styled-content style="fixed-case">BBT</styled-content> plus 50 mg ipragliflozin and/or 20 mg teneligliptin. Insulin doses were adjusted to maintain normal blood glucose levels. Plasma glucose profiles were estimated by continuous glucose monitoring before discharge. Required insulin doses were not significantly different among the treatment groups. The frequency of nocturnal hypoglycemia was significantly lower in the groups treated with ipragliflozin (6.5 &#x000b1; 10.6%) and ipragliflozin plus teneligliptin (6.9 &#x000b1; 14.3%) than in the group treated with <styled-content style="fixed-case">BBT</styled-content> alone (42 &#x000b1; 43.6%). The administration of sodium&#x02010;glucose co&#x02010;transporter 2 inhibitor with or without dipeptidyl peptidase&#x02010;4 inhibitor prevented nocturnal hypoglycemia in type 2 diabetes patients with <styled-content style="fixed-case">BBT</styled-content>.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jdi12588-kwd-0001">Basal&#x02013;bolus insulin therapy</kwd><kwd id="jdi12588-kwd-0002">Nocturnal hypoglycemia</kwd><kwd id="jdi12588-kwd-0003">Sodium&#x02010;glucose co&#x02010;transporter 2 inhibitor</kwd></kwd-group><funding-group><award-group><funding-source>Japan Society for the Promotion of Science</funding-source><award-id>#23653070</award-id></award-group></funding-group><counts><fig-count count="1"/><table-count count="3"/><page-count count="5"/><word-count count="3059"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jdi12588</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.0.9 mode:remove_FC converted:03.05.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jdi12588-cit-1001">
<source>J Diabetes Investig</source>
<year>2017</year>; <volume>8</volume>: <fpage>341</fpage>&#x02013;<lpage>345</lpage>
</mixed-citation>
</p></notes><notes><fn-group id="jdi12588-ntgp-0001"><fn id="jdi12588-note-1001"><p>
<bold>Clinical Trial Registry</bold>
</p><p>
<italic>University Hospital Medical Information Network</italic>
</p><p>UMIN000020742</p></fn></fn-group></notes></front><body><sec id="jdi12588-sec-0001"><title>Introduction</title><p>Insulin therapy strongly ameliorates hyperglycemia, but has adverse effects, such as hypoglycemia and weight gain, which might increase the incidence of cardiovascular events. These adverse events can be minimized by the initial use of insulin in combination with oral antidiabetic agents<xref rid="jdi12588-bib-0001" ref-type="ref">1</xref>. We and other investigators reported the efficacy of the addition of dipeptidyl peptidase&#x02010;4 inhibitors (DPP&#x02010;4I) to basal&#x02013;bolus insulin therapy (BBT)<xref rid="jdi12588-bib-0002" ref-type="ref">2</xref>, <xref rid="jdi12588-bib-0003" ref-type="ref">3</xref>.</p><p>Inhibition of sodium&#x02010;glucose co&#x02010;transporter 2 (SGLT2) increases urinary glucose extraction, leads to bodyweight reduction and ameliorates hyperglycemia<xref rid="jdi12588-bib-0004" ref-type="ref">4</xref>. The administration of empagliflozin was reported to reduce the incidence of cardiovascular death and hospitalization for heart failure<xref rid="jdi12588-bib-0005" ref-type="ref">5</xref>. However, the efficacy of the addition of SGLT2 inhibitor (SGLT2I) to BBT in type 2 diabetes patients was not well&#x02010;known.</p><p>In the present study, we evaluated the efficacy of the administration of SGLT2I and/or DPP&#x02010;4I to type 2 diabetes patients receiving basal&#x02013;bolus insulin therapy under short&#x02010;term hospitalization.</p></sec><sec id="jdi12588-sec-0002"><title>Methods</title><sec id="jdi12588-sec-0003"><title>Participants</title><p>We enrolled 60 patients with type 2 diabetes in an unblinded randomized study. The patients were aged 20&#x02013;75 years and visited the outpatient clinic of Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan, from July 2014 to October 2015, with a hemoglobin A<sub>1c</sub> level of &#x02265;10% at the first visit, and who agreed to hospitalization for diabetes control. Participants were excluded if they were treated with insulin or SGLT2I, were positive for antiglutamic acid decarboxylase antibody, or had a history or evidence of recent myocardial infarction, heart failure, cerebral vascular disease, endocrine disease or any carcinoma.</p></sec><sec id="jdi12588-sec-0004"><title>Study protocol and treatment</title><p>The protocol of the present study was approved by the ethics committee of Nippon Medical School Chiba Hokusoh Hospital (no. 526004), and was registered at UMIN Clinical Trials Registry (UMIN000020742). On admission, all participants stopped taking oral antidiabetic agents, received diet therapy and were randomly assigned to receive either insulin alone (Ins group; <italic>n</italic> = 15), insulin plus ipragliflozin (InsI group; <italic>n</italic> = 15), insulin plus teneligliptin (InsT group; <italic>n</italic> = 15) or insulin plus ipragliflozin and teneligliptin (InsIT group; <italic>n</italic> = 15).</p><p>The Ins group received basal&#x02013;bolus insulin therapy (BBT) with insulin glulisine and insulin glargine. Patients received BBT plus ipragliflozin 50 mg s.i.d. in the InsI group, BBT plus teneligliptin 50 mg s.i.d. in the InsT group, and BBT plus ipragliflozin 50 mg and teneligliptin 20 mg s.i.d. in the InsIT group. In all groups, the dose of insulin injection was adjusted to maintain the blood glucose levels before each meal within 90&#x02013;120 mg/dL by the attending physicians. The ophthalmologist checked diabetic retinopathy within 3 days after admission, and if required, fluorescent fundus angiography and retinal laser photocoagulation were immediately carried out.</p><p>Daily blood glucose profiles were also assessed using a continuous glucose monitoring (CGM) system (iPro&#x02122;2; Medtronic, Minneapolis, Minnesota, USA) for the last 2 days before discharge. To assess daily glycemic variability, the mean glucose, SD of the daily glucose and mean amplitude of glycemic excursion<xref rid="jdi12588-bib-0006" ref-type="ref">6</xref> were calculated using CGM data. When the glucose sensor of CGM showed &#x0003c;70 mg/dL, we considered the patients have hypoglycemia.</p></sec><sec id="jdi12588-sec-0005"><title>Statistical analysis</title><p>All analyses were carried out using the Jmp 12.2 software (SAS Institute, Cary, North Carolina, USA). Values are presented as mean &#x000b1; SD. Statistical analyses of sex differences and complication of diabetes at baseline were carried out using the &#x003c7;<sup>2</sup>
<italic>&#x02010;</italic>test. The significance of differences in the baseline characteristics and parameters of glycemic control before discharge among the four treatment groups was tested by analysis of variance (<sc>anova</sc>), with the least significant difference test as a <italic>post&#x02010;hoc</italic> test and Bonferroni correction for multiple comparisons. A <italic>P</italic>&#x02010;value of &#x0003c;0.05 was considered significant.</p></sec></sec><sec id="jdi12588-sec-0006"><title>Results</title><p>A total of 68 patients were assessed for eligibility, and 60 patients (56.9% men, mean age 56 &#x000b1; 12 years, body mass index 25.2 &#x000b1; 4.4 kg/m<sup>2</sup>, diabetes duration 7 &#x000b1; 11 years, hemoglobin A<sub>1c</sub> 12 &#x000b1; 2%, glycated albumin 30.9 &#x000b1; 8.5% and urinary C&#x02010;peptide immunoreactivity 72.9 &#x000b1; 50.3 &#x003bc;g/day) were selected. One patient dropped out because of the detection of malignancy in the InsI, and another patient in the InsT group dropped out because antiglutamic acid decarboxylase antibody was detected. There were no significant differences in the baseline characteristics among treatment groups (Table <xref rid="jdi12588-tbl-0001" ref-type="table-wrap">1</xref>).</p><table-wrap id="jdi12588-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline parameters of glycemic control, complications and medication before admission</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">Ins</th><th align="center" valign="top" rowspan="1" colspan="1">InsI</th><th align="center" valign="top" rowspan="1" colspan="1">InsT</th><th align="center" valign="top" rowspan="1" colspan="1">InsIT</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>P</italic>&#x02010;value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic>n</italic> (male)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">15 (8)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">14 (8)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">14 (8)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">15 (9)</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">55 &#x000b1; 14</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">57 &#x000b1; 8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">56 &#x000b1; 11</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">57 &#x000b1; 15</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration of diabetes (years)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">6 &#x000b1; 6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">9 &#x000b1; 11</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">9 &#x000b1; 17</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7 &#x000b1; 7</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">24.5 &#x000b1; 3.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">26.0 &#x000b1; 4.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">23.3 &#x000b1; 4.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">26.6 &#x000b1; 4.6</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">FPG (mg/dL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">217 &#x000b1; 59</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">226 &#x000b1; 63</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">212 &#x000b1; 44</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">220 &#x000b1; 58</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">HbA1c, % (NGSP)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">12.3 &#x000b1; 1.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">12.4 &#x000b1; 2.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">11.4 &#x000b1; 1.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">12 &#x000b1; 2</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">GA (%)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">32.3 &#x000b1; 7.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">30.1 &#x000b1; 9.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">29.9 &#x000b1; 7.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">31.1 &#x000b1; 9.2</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">U&#x02010;CPR (&#x003bc;g/day)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">75.1 &#x000b1; 45.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">73 &#x000b1; 61.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">81.3 &#x000b1; 50.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">62.9 &#x000b1; 46</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" colspan="6" rowspan="1">Complication</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Absent ATR (<italic>n</italic>)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">U&#x02010;Alb (mg/day)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">35.7 &#x000b1; 91.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">64.3 &#x000b1; 178.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">52.5 &#x000b1; 120</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">76.9 &#x000b1; 160</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" style="padding-left:10%" colspan="6" rowspan="1">DR</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">None (<italic>n</italic>)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">12</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">11</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">12</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">10</td><td align="center" rowspan="4" colspan="1">NS</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">SDR (<italic>n</italic>)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">3</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">PPDR (<italic>n</italic>)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">PDR (<italic>n</italic>)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0</td></tr><tr><td align="left" colspan="6" rowspan="1">Medication before admission</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">SU (<italic>n</italic>)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1</td><td align="center" rowspan="7" colspan="1">NS</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">SU + DPP (<italic>n</italic>)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">SU + BG (<italic>n</italic>)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">SU + BG + DPP (<italic>n</italic>)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">SU + &#x003b1;GI (<italic>n</italic>)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">SU + &#x003b1;GI + DPP (<italic>n</italic>)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">BG (<italic>n</italic>)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot><fn id="jdi12588-note-0002"><p>Data are expressed as mean &#x000b1; SD. <italic>P</italic>&#x02010;values for <sc>anova</sc> test or &#x003c7;<sup>2</sup>
<italic>&#x02010;</italic>test. &#x003b1;GI, alfa glucosidase inhibitor; ATR, Achilles tendon reflex; BG, biguanides; BMI, body mass index; DPP, dipeptidyl peptidase&#x02010;4 inhibitor; DR, diabetic retinopathy; FPG, fasting plasma glucose; GA, glycated albumin; HbA<sub>1c</sub>, hemoglobin A<sub>1c</sub>; Ins, insulin alone; InsI, insulin plus ipragliflozin; InsIT, insulin plus ipragliflozin and teneligliptin; InsT, insulin plus teneligliptin; NS, not significant; SU, sulfonylurea; U&#x02010;Alb, urinary albumin; U&#x02010;CPR, urinary C&#x02010;peptide immunoreactivity.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>The duration of hospitalization was 14 &#x000b1; 3, 14 &#x000b1; 4, 14 &#x000b1; 2, and 14 &#x000b1; 4 in the Ins, InsI, InsT and InsIT groups, respectively. The required insulin doses were not significantly different among treatment groups before discharge (Table <xref rid="jdi12588-tbl-0002" ref-type="table-wrap">2</xref>). No significant difference was found in the mean glucose, SD and mean amplitude of glycemic excursion levels among treatment groups (Table <xref rid="jdi12588-tbl-0003" ref-type="table-wrap">3</xref>; Figure <xref rid="jdi12588-fig-0001" ref-type="fig">1</xref>). The incidence of nocturnal hypoglycemia was significantly reduced in the InsI and InsIT groups compared with that in the Ins group (Table <xref rid="jdi12588-tbl-0003" ref-type="table-wrap">3</xref>; Figure <xref rid="jdi12588-fig-0001" ref-type="fig">1</xref>).</p><table-wrap id="jdi12588-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Required insulin dose before discharge</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">Ins</th><th align="center" valign="top" rowspan="1" colspan="1">InsI</th><th align="center" valign="top" rowspan="1" colspan="1">InsT</th><th align="center" valign="top" rowspan="1" colspan="1">InsIT</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>P</italic>&#x02010;value</th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1">Insulin glulisine</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Before breakfast (units)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">9 &#x000b1; 6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">8 &#x000b1; 5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7 &#x000b1; 4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7 &#x000b1; 4</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Before lunch (units)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">3 &#x000b1; 2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">3 &#x000b1; 2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">3 &#x000b1; 1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">3 &#x000b1; 3</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Before dinner (units)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7 &#x000b1; 3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">8 &#x000b1; 3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">6 &#x000b1; 3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">6 &#x000b1; 3</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" colspan="6" rowspan="1">Insulin glargine</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Bed time (units)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">12 &#x000b1; 8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">10 &#x000b1; 6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">12 &#x000b1; 8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">9 &#x000b1; 9</td><td align="center" rowspan="1" colspan="1">NS</td></tr></tbody></table><table-wrap-foot><fn id="jdi12588-note-0003"><p>Data are expressed as mean &#x000b1; SD. <italic>P</italic>&#x02010;values for <sc>anova</sc> test. InsI, insulin plus ipragliflozin; InsIT, insulin plus ipragliflozin and teneligliptin; InsT, insulin plus teneligliptin; NS, not significant.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><table-wrap id="jdi12588-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Continuous glucose monitoring parameters before discharge</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">Ins</th><th align="center" valign="top" rowspan="1" colspan="1">InsI</th><th align="center" valign="top" rowspan="1" colspan="1">InsT</th><th align="center" valign="top" rowspan="1" colspan="1">InsIT</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>P</italic>&#x02010;value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Mean (mg/dL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">110 &#x000b1; 19</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">120 &#x000b1; 14</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">114 &#x000b1; 18</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">114 &#x000b1; 12</td><td align="char" char="." rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">SD (mg/dL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">30 &#x000b1; 12</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">30 &#x000b1; 8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">28 &#x000b1; 12</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">26 &#x000b1; 8</td><td align="char" char="." rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">MAGE (mg/dL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">69 &#x000b1; 28</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">73 &#x000b1; 26</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">65 &#x000b1; 26</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">63 &#x000b1; 15</td><td align="char" char="." rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Frequency of glucose sensor &#x02264;70 mg/dL from 0.00 to 8.00 h (%)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">42 &#x000b1; 43.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">6.5 &#x000b1; 10.6<xref ref-type="fn" rid="jdi12588-note-0004">&#x02020;</xref>
</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">19 &#x000b1; 33</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">6.9 &#x000b1; 14.3<xref ref-type="fn" rid="jdi12588-note-0004">&#x02020;</xref>
</td><td align="center" rowspan="1" colspan="1">0.0093</td></tr></tbody></table><table-wrap-foot><fn id="jdi12588-note-0004"><p>Data are expressed as mean &#x000b1; SD. <italic>P</italic>&#x02010;values for <sc>anova</sc> test. <sup>&#x02020;</sup>Bonferroni <italic>post&#x02010;hoc</italic> analysis &#x0003c;0.05 vs insulin alone (Ins) group. InsI, insulin plus ipragliflozin; InsIT, insulin plus ipragliflozin and teneligliptin; InsT, insulin plus teneligliptin; MAGE, mean amplitude of glycemic excursions; NS, not significant; SD, standard deviation.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><fig fig-type="Figure" xml:lang="en" id="jdi12588-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Mean &#x000b1; <styled-content style="fixed-case">SD</styled-content> continuous glucose monitoring values before discharge. Mean values (solid black line) and the range of SD (gray area) in continuous glucose monitoring data before discharge in the (a) insulin alone group, (b) insulin plus ipragliflozin group, (c) insulin plus teneligliptin group and (d) insulin plus ipragliflozin and teneligliptin group.</p></caption><graphic id="nlm-graphic-3" xlink:href="JDI-8-341-g001"/></fig></sec><sec id="jdi12588-sec-0007"><title>Discussion</title><p>This was the first study to show that SGLT2I with and without DPP&#x02010;4I significantly prevents nocturnal hypoglycemia in patients with type 2 diabetes treated with BBT.</p><p>In the present study, the nocturnal glucose levels estimated by CGM in the Ins group were low, in the hypoglycemic range at a high frequency, and long term. However, administering SGLT2I with and without DPP&#x02010;4I prevented glucose level depression during the nocturnal phase. These data suggested that SGLT2I increased the serum insulin counter&#x02010;regulatory hormone (which mainly acts on the liver to increase hepatic gluconeogenesis<xref rid="jdi12588-bib-0007" ref-type="ref">7</xref>) concentrations, including glucagon, cortisol, growth hormone and/or catecholamine.</p><p>SGLT2I is known to increase hepatic glucose production by the increase of serum glucagon in type 2 diabetes patients<xref rid="jdi12588-bib-0008" ref-type="ref">8</xref>. SGLT2 is expressed in pancreatic &#x003b1;&#x02010;cells, and inhibiting SGLT2 induces glucagon secretion under normo&#x02010; to hypoglycemic conditions <italic>in vitro</italic>
<xref rid="jdi12588-bib-0009" ref-type="ref">9</xref>. DPP&#x02010;4I increases the concentration of plasma incretins, including glucagon&#x02010;like peptide&#x02010;1 and glucose&#x02010;dependent insulinotropic polypeptide<xref rid="jdi12588-bib-0010" ref-type="ref">10</xref>, <xref rid="jdi12588-bib-0011" ref-type="ref">11</xref>. Glucagon&#x02010;like peptide&#x02010;1 decreases and glucose&#x02010;dependent insulinotropic polypeptide increases the serum glucagon level<xref rid="jdi12588-bib-0012" ref-type="ref">12</xref>, <xref rid="jdi12588-bib-0013" ref-type="ref">13</xref>. Furthermore, DPP&#x02010;4I attenuates glucagon secretion under high&#x02010; to normoglycemic conditions, but not under hypoglycemic conditions<xref rid="jdi12588-bib-0014" ref-type="ref">14</xref>. Therefore, the modulation of glucagon secretion by the administration of SGLT2I with and without DPP&#x02010;4I seems to be one of the mechanisms that caused the preventive effect toward hypoglycemia as shown in the current study.</p><p>Furthermore, the Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA&#x02010;REG OUTCOME) study showed that SGLT2I reduced the incidence of cardiovascular mortality and hospitalization for heart failure in patients with type 2 diabetes<xref rid="jdi12588-bib-0005" ref-type="ref">5</xref>. Hypoglycemia activates sympathetic nerves to ameliorate hypoglycemia<xref rid="jdi12588-bib-0015" ref-type="ref">15</xref>, but might worsen heart failure<xref rid="jdi12588-bib-0016" ref-type="ref">16</xref>. In some clinical trials, hypoglycemia significantly increased mortality in patients with type 2 diabetes<xref rid="jdi12588-bib-0017" ref-type="ref">17</xref>, <xref rid="jdi12588-bib-0018" ref-type="ref">18</xref>. However, the impact of nocturnal hypoglycemia on cardiovascular mortality and hospitalization of heart failure remains unclear.</p><p>In conclusion, SGLT2I might have a preventive effect on nocturnal hypoglycemia. Further investigations on the effect of SGLT2I on serum insulin counter&#x02010;regulatory hormone concentration in the nocturnal phase, and the association between nocturnal hypoglycemia and complications are required.</p></sec><sec id="jdi12588-sec-0009"><title>Disclosure</title><p>The authors declare no conflict of interest.</p></sec></body><back><ack id="jdi12588-sec-0008"><title>Acknowledgments</title><p>This study was supported by Grants&#x02010;in&#x02010;Aid for Scientific Research from the Japan Society for the Promotion of Science (#23653070).</p></ack><ref-list content-type="cited-references" id="jdi12588-bibl-0001"><title>References</title><ref id="jdi12588-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jdi12588-cit-0001">
<string-name>
<surname>Donner</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Munoz</surname>
<given-names>M</given-names>
</string-name>. <article-title>Update on insulin therapy for type 2 diabetes</article-title>. <source>J Clin Endocrinol Metab</source>
<year>2012</year>; <volume>97</volume>: <fpage>1405</fpage>&#x02013;<lpage>1413</lpage>.<pub-id pub-id-type="pmid">22442275</pub-id></mixed-citation></ref><ref id="jdi12588-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jdi12588-cit-0002">
<string-name>
<surname>Okajima</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Emoto</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kato</surname>
<given-names>K</given-names>
</string-name>, <italic>et al</italic>
<article-title>Effect of glycemic control on chylomicron metabolism and correlation between postprandial metabolism of plasma glucose and chylomicron in patients with type 2 diabetes treated with basal&#x02010;bolus insulin therapy with or without Vildagliptin</article-title>. <source>J Atheroscler Thromb</source>
<year>2016</year>. doi: <ext-link ext-link-type="doi" xlink:href="10.5551/jat.32409">10.5551/jat.32409</ext-link>.</mixed-citation></ref><ref id="jdi12588-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jdi12588-cit-0003">
<string-name>
<surname>Shimoda</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Iwashita</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ichimori</surname>
<given-names>S</given-names>
</string-name>, <italic>et al</italic>
<article-title>Efficacy and safety of sitagliptin as add&#x02010;on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy</article-title>. <source>Endocr J</source>
<year>2013</year>; <volume>60</volume>: <fpage>1207</fpage>&#x02013;<lpage>1214</lpage>.<pub-id pub-id-type="pmid">23912974</pub-id></mixed-citation></ref><ref id="jdi12588-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jdi12588-cit-0004">
<string-name>
<surname>Rajeev</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Cuthbertson</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Wilding</surname>
<given-names>JP</given-names>
</string-name>. <article-title>Energy balance and metabolic changes with sodium&#x02010;glucose co&#x02010;transporter 2 inhibition</article-title>. <source>Diabetes Obes Metab</source>
<year>2016</year>; <volume>18</volume>: <fpage>125</fpage>&#x02013;<lpage>134</lpage>.<pub-id pub-id-type="pmid">26403227</pub-id></mixed-citation></ref><ref id="jdi12588-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jdi12588-cit-0005">
<string-name>
<surname>Zinman</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Wanner</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Lachin</surname>
<given-names>JM</given-names>
</string-name>, <italic>et al</italic>
<article-title>Investigators E&#x02010;RO: Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes</article-title>. <source>N Engl J Med</source>
<year>2015</year>; <volume>373</volume>: <fpage>2117</fpage>&#x02013;<lpage>2128</lpage>.<pub-id pub-id-type="pmid">26378978</pub-id></mixed-citation></ref><ref id="jdi12588-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jdi12588-cit-0006">
<string-name>
<surname>Service</surname>
<given-names>FJ</given-names>
</string-name>, <string-name>
<surname>Molnar</surname>
<given-names>GD</given-names>
</string-name>, <string-name>
<surname>Rosevear</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Ackerman</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Gatewood</surname>
<given-names>LC</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>
<given-names>WF</given-names>
</string-name>. <article-title>Mean amplitude of glycemic excursions, a measure of diabetic instability</article-title>. <source>Diabetes</source>
<year>1970</year>; <volume>19</volume>: <fpage>644</fpage>&#x02013;<lpage>655</lpage>.<pub-id pub-id-type="pmid">5469118</pub-id></mixed-citation></ref><ref id="jdi12588-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jdi12588-cit-0007">
<string-name>
<surname>Cryer</surname>
<given-names>PE</given-names>
</string-name>. <article-title>Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes</article-title>. <source>Endocrinology</source>
<year>2012</year>; <volume>153</volume>: <fpage>1039</fpage>&#x02013;<lpage>1048</lpage>.<pub-id pub-id-type="pmid">22166985</pub-id></mixed-citation></ref><ref id="jdi12588-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jdi12588-cit-0008">
<string-name>
<surname>Merovci</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Solis&#x02010;Herrera</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Daniele</surname>
<given-names>G</given-names>
</string-name>, <italic>et al</italic>
<article-title>Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production</article-title>. <source>J Clin Investig</source>
<year>2014</year>; <volume>124</volume>: <fpage>509</fpage>&#x02013;<lpage>514</lpage>.<pub-id pub-id-type="pmid">24463448</pub-id></mixed-citation></ref><ref id="jdi12588-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jdi12588-cit-0009">
<string-name>
<surname>Bonner</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kerr&#x02010;Conte</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Gmyr</surname>
<given-names>V</given-names>
</string-name>, <italic>et al</italic>
<article-title>Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion</article-title>. <source>Nat Med</source>
<year>2015</year>; <volume>21</volume>: <fpage>512</fpage>&#x02013;<lpage>517</lpage>.<pub-id pub-id-type="pmid">25894829</pub-id></mixed-citation></ref><ref id="jdi12588-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jdi12588-cit-0010">
<string-name>
<surname>Drucker</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Enhancing incretin action for the treatment of type 2 diabetes</article-title>. <source>Diabetes Care</source>
<year>2003</year>; <volume>26</volume>: <fpage>2929</fpage>&#x02013;<lpage>2940</lpage>.<pub-id pub-id-type="pmid">14514604</pub-id></mixed-citation></ref><ref id="jdi12588-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jdi12588-cit-0011">
<string-name>
<surname>Panina</surname>
<given-names>G</given-names>
</string-name>. <article-title>The DPP&#x02010;4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond</article-title>. <source>Diabetes Obes Metab</source>
<year>2007</year>; <volume>9</volume>(<issue>Suppl 1</issue>): <fpage>32</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">17877545</pub-id></mixed-citation></ref><ref id="jdi12588-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jdi12588-cit-0012">
<string-name>
<surname>Hare</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Vilsboll</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Asmar</surname>
<given-names>M</given-names>
</string-name>, <italic>et al</italic>
<article-title>The glucagonostatic and insulinotropic effects of glucagon&#x02010;like peptide 1 contribute equally to its glucose&#x02010;lowering action</article-title>. <source>Diabetes</source>
<year>2010</year>; <volume>59</volume>: <fpage>1765</fpage>&#x02013;<lpage>1770</lpage>.<pub-id pub-id-type="pmid">20150286</pub-id></mixed-citation></ref><ref id="jdi12588-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jdi12588-cit-0013">
<string-name>
<surname>Christensen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Vedtofte</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Holst</surname>
<given-names>JJ</given-names>
</string-name>, <italic>et al</italic>
<article-title>Glucose&#x02010;dependent insulinotropic polypeptide: a bifunctional glucose&#x02010;dependent regulator of glucagon and insulin secretion in humans</article-title>. <source>Diabetes</source>
<year>2011</year>; <volume>60</volume>: <fpage>3103</fpage>&#x02013;<lpage>3109</lpage>.<pub-id pub-id-type="pmid">21984584</pub-id></mixed-citation></ref><ref id="jdi12588-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jdi12588-cit-0014">
<string-name>
<surname>Ahren</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Schweizer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Dejager</surname>
<given-names>S</given-names>
</string-name>, <italic>et al</italic>
<article-title>Vildagliptin enhances islet responsiveness to both hyper&#x02010; and hypoglycemia in patients with type 2 diabetes</article-title>. <source>J Clin Endocrinol Metab</source>
<year>2009</year>; <volume>94</volume>: <fpage>1236</fpage>&#x02013;<lpage>1243</lpage>.<pub-id pub-id-type="pmid">19174497</pub-id></mixed-citation></ref><ref id="jdi12588-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jdi12588-cit-0015">
<string-name>
<surname>Abramson</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Arky</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Woeber</surname>
<given-names>KA</given-names>
</string-name>. <article-title>Effects of propranolol on the hormonal and metabolic responses to insulin&#x02010;induced hypoglycaemia</article-title>. <source>Lancet</source>
<year>1966</year>; <volume>2</volume>: <fpage>1386</fpage>&#x02013;<lpage>1388</lpage>.<pub-id pub-id-type="pmid">4163545</pub-id></mixed-citation></ref><ref id="jdi12588-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jdi12588-cit-0016">
<string-name>
<surname>Koivikko</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Tulppo</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Kiviniemi</surname>
<given-names>AM</given-names>
</string-name>, <italic>et al</italic>
<article-title>Autonomic cardiac regulation during spontaneous nocturnal hypoglycemia in patients with type 1 diabetes</article-title>. <source>Diabetes Care</source>
<year>2012</year>; <volume>35</volume>: <fpage>1585</fpage>&#x02013;<lpage>1590</lpage>.<pub-id pub-id-type="pmid">22611064</pub-id></mixed-citation></ref><ref id="jdi12588-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jdi12588-cit-0017">
<string-name>
<surname>Bonds</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Bergenstal</surname>
<given-names>RM</given-names>
</string-name>, <italic>et al</italic>
<article-title>The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study</article-title>. <source>BMJ</source>
<year>2010</year>; <volume>340</volume>: <fpage>b4909</fpage>.<pub-id pub-id-type="pmid">20061358</pub-id></mixed-citation></ref><ref id="jdi12588-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jdi12588-cit-0018">
<string-name>
<surname>Zoungas</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Chalmers</surname>
<given-names>J</given-names>
</string-name>, <italic>et al</italic>
<article-title>Severe hypoglycemia and risks of vascular events and death</article-title>. <source>N Engl J Med</source>
<year>2010</year>; <volume>363</volume>: <fpage>1410</fpage>&#x02013;<lpage>1418</lpage>.<pub-id pub-id-type="pmid">20925543</pub-id></mixed-citation></ref></ref-list></back></article>